258 related articles for article (PubMed ID: 28467918)
1. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
2. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
Delaloge S; Wolp-Diniz R; Byrski T; Blum JL; Gonçalves A; Campone M; Lardelli P; Kahatt C; Nieto A; Cullell-Young M; Lubinski J
Ann Oncol; 2014 Jun; 25(6):1152-8. PubMed ID: 24692579
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.
Blum JL; Gonçalves A; Efrat N; Debled M; Conte P; Richards PD; Richards D; Lardelli P; Nieto A; Cullell-Young M; Delaloge S
Breast Cancer Res Treat; 2016 Jan; 155(2):295-302. PubMed ID: 26749361
[TBL] [Abstract][Full Text] [Related]
5. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
[TBL] [Abstract][Full Text] [Related]
6. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
[TBL] [Abstract][Full Text] [Related]
9. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
Boni V; Pistilli B; Braña I; Shapiro GI; Trigo J; Moreno V; Castellano D; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Longo F; Zaman K; Antón A; Paredes A; Huidobro G; Subbiah V
ESMO Open; 2022 Oct; 7(5):100571. PubMed ID: 36037567
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
12. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
McMeekin DS; Lisyanskaya A; Crispens M; Oza AM; Braly P; Doering D; Bayever E; Michiels B; Markman M
Gynecol Oncol; 2009 Aug; 114(2):288-92. PubMed ID: 19476988
[TBL] [Abstract][Full Text] [Related]
13. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
Ferrandina G; Salutari V; Vincenzi B; Marinaccio M; Naglieri E; Loizzi V; Carpano S; Amadio G; Tonini G; Scambia G; Lorusso D
Gynecol Oncol; 2013 Sep; 130(3):505-10. PubMed ID: 23774301
[TBL] [Abstract][Full Text] [Related]
15. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin mechanism of action and platinum resistance: molecular rationale.
Ray-Coquard I
Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
[TBL] [Abstract][Full Text] [Related]
17. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Adam JP; Boumedien F; Letarte N; Provencher D
Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
[TBL] [Abstract][Full Text] [Related]
20. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
